ARL6

Across TCGA pan-cancer cohorts, ARL6 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARL6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARL6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARL6 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and COAD are the cancer types where ARL6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.820	<.001	9	view →
LSCC	Female	All	−0.710	<.001	9	view →
COAD	Male	II,III,IV	−0.801	<.001	8	view →
PDAC	Female	All	−0.284	.009	3	view →
HNSC	Female	IV	+0.205	.047	1	view →
CCRCC	All	All	−0.073	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARL6–LUAD

Open the LUAD breakdown →